Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
Summary : Topline data of the main cohort of AAVance clinical trial expected in Q3 2022 Stabilization or decreased size of white…